Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial)

International Journal of Cardiology

Volumn 205, Issue , 2016, Pages 23-30

  Brenner, Christoph ^a,b   Adrion, Christine ^c   Grabmaier, Ulrich ^b   Theisen, Daniel ^b   Von Ziegler, Franz ^b   Leber, Alexander ^d   Becker, Alexander ^b   Sohn, Hae Young ^b   Hoffmann, Ellen ^d   Mansmann, Ulrich ^c   Steinbeck, Gerhard ^b   Franz, Wolfgang Michael ^a,b   Theiss, Hans Diogenes ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

Acute myocardial infarction; Granulocyte colony stimulating factor; Progenitor cell therapy; Sitagliptin

Indexed keywords

LENOGRASTIM; PLACEBO; SITAGLIPTIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; ADVERSE EFFECTS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEART STROKE VOLUME; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; STEM CELL TRANSPLANTATION; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84955474147     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.11.180     Document Type: Article

References (29)

1. J.M. Hill, G. Zalos, J.P. Halcox, and et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk N. Engl. J. Med. 348 2003 593 600
2. A.A. Kocher, M.D. Schuster, M.J. Szabolcs, and et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function Nat. Med. 7 2001 430 436
3. M.M. Zaruba, H.D. Theiss, M. Vallaster, and et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell Stem Cell 4 2009 313 323
4. A.T. Askari, S. Unzek, Z.B. Popovic, and et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet 362 2003 697 703
5. D.J. Ceradini, A.R. Kulkarni, M.J. Callaghan, and et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat. Med. 10 2004 858 864
6. K.W. Christopherson II, G. Hangoc, C.R. Mantel, and H.E. Broxmeyer Modulation of hematopoietic stem cell homing and engraftment by CD26 Science 305 2004 1000 1003
7. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
8. H.D. Theiss, L. Gross, M. Vallaster, and et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction Int. J. Cardiol. 168 2013 3359 3369
9. C. Brenner, N. Krankel, S. Kuhlenthal, and et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells Int. J. Cardiol. 177 2014 266 275
10. S. Rafii, Z. Cao, R. Lis, and et al. Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration Nat. Cell Biol. 17 2015 123 136
11. M.S. Penn SDF-1:CXCR4 axis is fundamental for tissue preservation and repair Am. J. Pathol. 177 2010 2166 2168
12. L. Salcedo, N. Sopko, H.H. Jiang, M. Damaser, M. Penn, and M. Zutshi Chemokine upregulation in response to anal sphincter and pudendal nerve injury: potential signals for stem cell homing Int. J. Color. Dis. 26 2011 1577 1581
13. H.D. Theiss, M. Vallaster, C. Rischpler, and et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis Stem Cell Res. 7 2011 244 255
14. H.D. Theiss, C. Brenner, M.G. Engelmann, and et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-trial) - rationale, design and first interim analysis Int. J. Cardiol. 145 2010 282 284
15. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction J. Am. Coll. Cardiol. 50 2007 2173 2195
16. V. Schachinger, S. Erbs, A. Elsasser, and et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction N. Engl. J. Med. 355 2006 1210 1221
17. T. Friede, and M. Kieser Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis Pharm. Stat. 10 2011 8 13
18. M. Kieser, and T. Friede Simple procedures for blinded sample size adjustment that do not affect the type I error rate Stat. Med. 22 2003 3571 3581
19. R Core Team A Language and Environment for Statistical Computing 2013 R Foundation for Statistical Computing Vienna, Austria http://www.R-project.org
20. W.B. White, C.P. Cannon, S.R. Heller, and et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
21. J.B. Green, M.A. Bethel, P.W. Armstrong, and et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N. Engl. J. Med. 373 2015 232 242
22. M.G. Engelmann, H.D. Theiss, C. Hennig-Theiss, and et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (granulocyte colony-stimulating factor ST-segment elevation myocardial infarction) trial J. Am. Coll. Cardiol. 48 2006 1712 1721
23. D. Zohlnhofer, A. Dibra, T. Koppara, and et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis J. Am. Coll. Cardiol. 51 2008 1429 1437
24. D. Zohlnhofer, I. Ott, J. Mehilli, and et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial JAMA 295 2006 1003 1010
25. K. Moazzami, A. Roohi, and B. Moazzami Granulocyte colony stimulating factor therapy for acute myocardial infarction Cochrane Database Syst. Rev. 5 2013 CD008844
26. E. Deindl, M.M. Zaruba, S. Brunner, and et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis FASEB J. 20 2006 956 958
27. D. Orlic, J. Kajstura, S. Chimenti, and et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival Proc. Natl. Acad. Sci. U. S. A. 98 2001 10344 10349
28. M.E. Cox, J. Rowell, L. Corsino, and J.B. Green Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy Drug Healthc. Patient Saf. 2 2010 7 19
29. S.J. Reinstadler, H.J. Feistritzer, G. Klug, and et al. High-sensitivity troponin T for prediction of left ventricular function and infarct size one year following ST-elevation myocardial infarction Int. J. Cardiol. 202 2015 188 193